Abstract:Purpose To investigate the correlation between protein expression of breast cancer susceptibility gene 1 ( BRCA1 ) and topoisomerase IIβ-binding protein 1 (TopBP1) and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy. Methods Immunohistochemical staining was conducted to detect the protein expression of BRCA1 and TopBP1 in 101 cases of NSCLC and to correlate these with clinical features, disease progression, and patient survival. Chi-square test ( χ 2 -test) was used to evaluate categorical variables. Spearman’s rank order correlation was used to analyze continuous variables. Overall survival rate of NSCLC patients was analyzed by Kaplan–Meier survival curve and log-rank test. Relevant factors affecting the survival of patients with advanced NSCLC were analyzed by COX proportional hazards regression model. Results A total of 101 NSCLC patients were included in the present study. In tumor tissue specimens, positive expression rates of BRCA1 and TopBP1 proteins were 51.5 and 57.4 %, respectively. A significant correlation between the positive expression of BRCA1 and the positive expression of TopBP1 was observed ( P < 0.001, r = 0.326). No significant correlation between BRCA1/TopBP1 and age, gender, smoking status, performance status score, pathohistological type, or clinical stage was detected ( P > 0.05). During the follow-up period, 65 patients died, and 86 patients showed progression at the end of the study. The survival rate of patients with negative BRCA1 protein expression was higher than that in patients with positive BRCA1 protein expression [median overall survival (OS) 34 vs. 21 months, HR 1.913, 95 % CI 1.161–3.150, P = 0.011]. Similarly, the survival rate of patients with negative TopBP1 expression was higher than that in patients with positive TopBP1 (median OS 36 vs. 23 months, HR 1.931, 95 % CI 1.157–3.224, P = 0.012). No significant correlation between protein expression of BRCA1 or TopBP1 with NSCLC disease progression was observed ( P > 0.05). Conclusions The present study indicates NSCLC patients with negative BRCA1 and TopBP1 expression showed better prognosis than those with positive protein expression.

The BRCA1 Mrna and RAP80 Mrna Expression Levels in Relation to Clinicopathological Characteristics in Advanced Non-Small Cell Lung Cancer

Expression of ERCC1 and BRCA1 Predict the Clinical Outcome of Non-Small Cell Lung Cancer in Patients Receiving Platinum-Based Chemotherapy.

RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference Between Mrna and Protein Expression in Predicting Prognosis of Breast Cancer Patients

Effect of RRM1 and BRCA1 Expressions on Efficiency of Gemcitabine and Platinum in Patients with Advanced Non-Small Cell Lung Cancer

Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy

RRM1 Gene Expression in Peripheral Blood is Predictive of Shorter Survival in Chinese Patients with Advanced Non-Small-cell Lung Cancer Treated by Gemcitabine and Platinum

XPG Mrna Expression Levels Modulate Prognosis in Resected Non–Small-Cell Lung Cancer in Conjunction with BRCA1 and ERCC1 Expression

First-line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients.

EP1.03-28 Frequency and Molecular Characteristics of BRCA1 Mutations in Non-Small Cell Lung Cancer from East Asian Patients

Abnormal Expression and Clinical Significance of Telomeric Repeat Binding Factor 1 and Tankyrase 1 in Non-small Cell Lung Cancer

Expression of Telomeric Repeat Binding Factor 1 in Non-Small Cell Lung Cancer.

Expression of ATM , CHK 2 and BRCA 1 predicts the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy

[A study on the relationship between the level of E-cadherin mRNA expression and pathological characteristics of non-small cell lung cancer].

Expression and clinical study of vascular endothelial growth factor and its receptors FLT-1, FLK-1/KDR in non-small cell lung cancer

Chinese multicenter randomized trial of customized chemotherapy based on BRCA1 (breast cancer susceptibility gene 1)-RAP80 (receptora-ssociaet d protein 80) mRNA expr ession ina dvanced non-small cell lu ng cancer (NSCLC) pa tients

Relation between the expression of ERCC1 and the clinicopathology characteristics in advanced non-small cell lung cancer

Predictive Value of BRCA1/2 Mrna Expression for Response to Neoadjuvant Chemotherapy in BRCA‐negative Breast Cancers

The expression of human antigen R and vascular endothelial growth factor-C and their significance in non-small cell lung cancer]

BRCA1 Mrna Expression As a Predictive and Prognostic Marker in Advanced Esophageal Squamous Cell Carcinoma Treated with Cisplatin- or Docetaxel-Based Chemotherapy/Chemoradiotherapy

Prognostic Significance of ERCC1 Mrna Expression in Patients with Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1